Australia
Recce Pharmaceuticals Ltd (ASX:RCE) is a biotechnology and pharmaceutical company that is pioneering the development and commercialization of a new class of synthetic antibiotics with broad-spectrum activity. The company aims to address the urgent global health problem of antibiotic-resistant superbugs. Their patented lead candidate, known as RECCE® 327, has shown promise in pre-clinical testing for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms.
Founded in 2008 and headquartered in Australia, Recce Pharmaceuticals has garnered significant attention and support. With a recent $3.00M grant investment from the U.S. Department of Defense in July 15, 2024, the company has further validated its potential. They have manufacturing facilities in Australia and clinical research partners in the USA.
Their innovative approach and promising preclinical results make Recce Pharmaceuticals a compelling player in the fight against antimicrobial resistance and viral pathogens, offering potential for significant impact in the biotechnology and pharmaceutical industries.
